Pink Sheet
Scrip
Medtech Insight
HBW Insight
Generics Bulletin
In Vivo
Pink Sheet
Scrip
Medtech Insight
HBW Insight
Generics Bulletin
In Vivo
Medicare Negotiations 2.0 Slash Prices Up To 85%, But Mean Cuts Barely Budge
Nov 26 2025
•
By
Manas Mishra
The negotiations included Novo Nordisk's semaglutide, Merck's Janumet and AbbVie's Linzess.
(Shutterstock)
Learn what's happening at the US FDA. On the go.
Derrick Gingery and the team bring you a weekly "Drug Fix".
More from Medicare
More from Government Payers